Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 4:11:1344.
doi: 10.3389/fphar.2020.01344. eCollection 2020.

Montelukast Drug May Improve COVID-19 Prognosis: A Review of Evidence

Jean Barré  1 , Jean-Marc Sabatier  2 , Cédric Annweiler  1   3   4
Affiliations

Montelukast Drug May Improve COVID-19 Prognosis: A Review of Evidence

Jean Barré et al. Front Pharmacol. .

Abstract

With the lack of effective therapy, chemoprevention and vaccination, focusing on the immediate repurposing of existing drugs gives hope of curbing the pandemic. Interestingly, montelukast, a drug usually used in asthma, may be proposed as a potential adjuvant therapy in COVID-19. The aim of the present article was to review the properties of montelukast that could be beneficial in COVID-19. Ten experimentally supported properties were retrieved, either related to SARS-CoV-2 (antiviral properties, prevention of endotheliitis and of neurological disorders linked to SARS-CoV-2), and/or related to the host (improvement of atherogenic vascular inflammation, limitation of the ischemia/reperfusion phenomenon, improvement of respiratory symptoms), and/or related to serious COVID-19 outcomes (limitation of the cytokine storm, mitigation of acute respiratory distress syndrome), and/or related to tissue sequelae (antioxidant properties, anti-fibrosis effects). Based on gathered theoretical evidence, we argue that montelukast should be further tested to prevent and treat COVID-19 outcomes.

Keywords: coronavirus disease 2019; lukasts; montelukast; research; severe acute respiratory syndrome coronavirus 2; treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Experimentally supported properties of Cyst LT1 receptor antagonists potentially beneficial in COVID-19.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ahn D. G., Shin H. J., Kim M. H., Lee S., Kim H. S., Myoung J., et al. (2020). Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). J. Microbiol. Biotechnol. 30, 313–324. 10.4014/jmb.2003.03011 - DOI - PMC - PubMed
    1. Al-Amran F. G., Hadi N. R., Hashim A. M. (2013). Cysteinyl leukotriene receptor antagonist montelukast ameliorates acute lung injury following haemorrhagic shock in rats. Eur. J. Cardiothorac. Surg. 43, 421–427. 10.1093/ejcts/ezs312 - DOI - PubMed
    1. Allen S. P., Dashwood M. R., Chester A. H., Tadjkarimi S., Collins M., Piper P. J., et al. (1993). Influence of Atherosclerosis on the Vascular Reactivity of Isolated Human Epicardial Coronary Arteries to Leukotriene C4. Cardioscience 4, 47–54. - PubMed
    1. Almerie M. Q., Kerrigan D. D. (2020). The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast. Med. Hypotheses 143, 109883. 10.1016/j.mehy.2020.109883 - DOI - PMC - PubMed
    1. Aquino-Junior J. C. J., Brito A. A., Rigonato-Oliveira N. C., Damaceno-Rodrigues N. R., Oliveira A. P. L., Silva A. P., et al. (2019). Montelukast, Leukotriene Inhibitor, Reduces LPS-Induced Acute Lung Inflammation and Human Neutrophil Activation. Arch. Bronconeumol. 55, 573–580. 10.1016/j.arbres.2019.05.003 - DOI - PubMed